284 related articles for article (PubMed ID: 12923074)
21. Friedreich ataxia: the oxidative stress paradox.
Seznec H; Simon D; Bouton C; Reutenauer L; Hertzog A; Golik P; Procaccio V; Patel M; Drapier JC; Koenig M; Puccio H
Hum Mol Genet; 2005 Feb; 14(4):463-74. PubMed ID: 15615771
[TBL] [Abstract][Full Text] [Related]
22. Is antioxidant potential of the mitochondrial targeted ubiquinone derivative MitoQ conserved in cells lacking mtDNA?
Lu C; Zhang D; Whiteman M; Armstrong JS
Antioxid Redox Signal; 2008 Mar; 10(3):651-60. PubMed ID: 17999633
[TBL] [Abstract][Full Text] [Related]
23. Targeting antioxidants to mitochondria and cardiovascular diseases: the effects of mitoquinone.
Milagros Rocha M; Victor VM
Med Sci Monit; 2007 Jul; 13(7):RA132-45. PubMed ID: 17599037
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of apoptotic markers in HEI-OC1 cells treated with gentamicin with and without the mitochondria-targeted antioxidant mitoquinone.
Jadidian A; Antonelli PJ; Ojano-Dirain CP
Otol Neurotol; 2015 Mar; 36(3):526-30. PubMed ID: 25076226
[TBL] [Abstract][Full Text] [Related]
25. Coenzyme Q10 and vitamin E deficiency in Friedreich's ataxia: predictor of efficacy of vitamin E and coenzyme Q10 therapy.
Cooper JM; Korlipara LV; Hart PE; Bradley JL; Schapira AH
Eur J Neurol; 2008 Dec; 15(12):1371-9. PubMed ID: 19049556
[TBL] [Abstract][Full Text] [Related]
26. Oxidative stress, mitochondrial dysfunction and cellular stress response in Friedreich's ataxia.
Calabrese V; Lodi R; Tonon C; D'Agata V; Sapienza M; Scapagnini G; Mangiameli A; Pennisi G; Stella AM; Butterfield DA
J Neurol Sci; 2005 Jun; 233(1-2):145-62. PubMed ID: 15896810
[TBL] [Abstract][Full Text] [Related]
27. Protective effect of mitochondrial-targeted antioxidant MitoQ against iron ion
Gan L; Wang Z; Si J; Zhou R; Sun C; Liu Y; Ye Y; Zhang Y; Liu Z; Zhang H
Toxicol Appl Pharmacol; 2018 Feb; 341():1-7. PubMed ID: 29317239
[TBL] [Abstract][Full Text] [Related]
28. Mitochondria-targeted antioxidant MitoQ reduces gentamicin-induced ototoxicity.
Ojano-Dirain CP; Antonelli PJ; Le Prell CG
Otol Neurotol; 2014 Mar; 35(3):533-9. PubMed ID: 24518411
[TBL] [Abstract][Full Text] [Related]
29. Estrogen prevents oxidative damage to the mitochondria in Friedreich's ataxia skin fibroblasts.
Richardson TE; Yu AE; Wen Y; Yang SH; Simpkins JW
PLoS One; 2012; 7(4):e34600. PubMed ID: 22509330
[TBL] [Abstract][Full Text] [Related]
30. Mitochondria-targeted antioxidants protect pancreatic β-cells against oxidative stress and improve insulin secretion in glucotoxicity and glucolipotoxicity.
Lim S; Rashid MA; Jang M; Kim Y; Won H; Lee J; Woo JT; Kim YS; Murphy MP; Ali L; Ha J; Kim SS
Cell Physiol Biochem; 2011; 28(5):873-86. PubMed ID: 22178940
[TBL] [Abstract][Full Text] [Related]
31. Contradictory effects of mitochondria- and non-mitochondria-targeted antioxidants on hepatocarcinogenesis by altering DNA repair in mice.
Wang B; Fu J; Yu T; Xu A; Qin W; Yang Z; Chen Y; Wang H
Hepatology; 2018 Feb; 67(2):623-635. PubMed ID: 28898446
[TBL] [Abstract][Full Text] [Related]
32. Therapeutic approaches for the treatment of Friedreich's ataxia.
Strawser CJ; Schadt KA; Lynch DR
Expert Rev Neurother; 2014 Aug; 14(8):949-57. PubMed ID: 25034024
[TBL] [Abstract][Full Text] [Related]
33. Interaction of the mitochondria-targeted antioxidant MitoQ with phospholipid bilayers and ubiquinone oxidoreductases.
James AM; Sharpley MS; Manas AR; Frerman FE; Hirst J; Smith RA; Murphy MP
J Biol Chem; 2007 May; 282(20):14708-18. PubMed ID: 17369262
[TBL] [Abstract][Full Text] [Related]
34. Animal and human studies with the mitochondria-targeted antioxidant MitoQ.
Smith RA; Murphy MP
Ann N Y Acad Sci; 2010 Jul; 1201():96-103. PubMed ID: 20649545
[TBL] [Abstract][Full Text] [Related]
35. Protection against renal ischemia-reperfusion injury in vivo by the mitochondria targeted antioxidant MitoQ.
Dare AJ; Bolton EA; Pettigrew GJ; Bradley JA; Saeb-Parsy K; Murphy MP
Redox Biol; 2015 Aug; 5():163-168. PubMed ID: 25965144
[TBL] [Abstract][Full Text] [Related]
36. Consequences of long-term oral administration of the mitochondria-targeted antioxidant MitoQ to wild-type mice.
Rodriguez-Cuenca S; Cochemé HM; Logan A; Abakumova I; Prime TA; Rose C; Vidal-Puig A; Smith AC; Rubinsztein DC; Fearnley IM; Jones BA; Pope S; Heales SJ; Lam BY; Neogi SG; McFarlane I; James AM; Smith RA; Murphy MP
Free Radic Biol Med; 2010 Jan; 48(1):161-72. PubMed ID: 19854266
[TBL] [Abstract][Full Text] [Related]
37. Friedreich Ataxia: current state-of-the-art, and future prospects for mitochondrial-focused therapies.
Pallardó FV; Pagano G; Rodríguez LR; Gonzalez-Cabo P; Lyakhovich A; Trifuoggi M
Transl Res; 2021 Mar; 229():135-141. PubMed ID: 32841735
[TBL] [Abstract][Full Text] [Related]
38. Friedreich's ataxia: coenzyme Q10 and vitamin E therapy.
Cooper JM; Schapira AH
Mitochondrion; 2007 Jun; 7 Suppl():S127-35. PubMed ID: 17485244
[TBL] [Abstract][Full Text] [Related]
39. The mitochondria-targeted anti-oxidant MitoQ protects against intervertebral disc degeneration by ameliorating mitochondrial dysfunction and redox imbalance.
Kang L; Liu S; Li J; Tian Y; Xue Y; Liu X
Cell Prolif; 2020 Mar; 53(3):e12779. PubMed ID: 32020711
[TBL] [Abstract][Full Text] [Related]
40. Pharmacological treatments for Friedreich ataxia.
Kearney M; Orrell RW; Fahey M; Brassington R; Pandolfo M
Cochrane Database Syst Rev; 2016 Aug; 2016(8):CD007791. PubMed ID: 27572719
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
